Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5638 Target Snapshot

Serine/threonine-protein kinase Nek11 · SINGLE PROTEIN · Homo sapiens

510Compounds
138Assays
4Approved Drugs
87.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q8NG66. Use UniProt Q8NG66 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8NG66 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase Nek11 as ChEMBL target CHEMBL5638, mapped to UniProt Q8NG66. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase Nek11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5638
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8NG66
Serine/threonine-protein kinase Nek11
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase Nek11 is the right protein anchor across sources, using UniProt Q8NG66 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase Nek11
UniProt AccessionQ8NG66
Component TypeProtein
Sequence Length645 aa

Serine/threonine-protein kinase Nek11

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase Nek11, mapped to UniProt Q8NG66. Sequence length is 645 aa.

Mapped IDQ8NG66
Review nameSerine/threonine-protein kinase Nek11
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC509.0
KI1.0
KD77.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL475251 6.77 Kd 170.0 Clinical
CHEMBL1229517 6.72 Kd 190.0 Approved
CHEMBL1230020 6.72 Kd 190.0 Preclinical
CHEMBL388978 6.54 IC50 290.0 Preclinical
CHEMBL5416410 6.33 Kd 470.0 Approved
CHEMBL288441 6.19 Kd 650.0 Approved
CHEMBL4088216 6.0 IC50 1000.0 Preclinical
CHEMBL4097778 6.0 IC50 1000.0 Preclinical
CHEMBL4549667 6.0 IC50 1000.0 Preclinical
CHEMBL1908396 5.96 Kd 1100.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
6
5.5
7
6.0
5
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BOSUTINIB
CHEMBL288441
Approved 2012
VEMURAFENIB
CHEMBL1229517
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
Assay Landscape

Assay Landscape

138
Total Assays
12
Tested Compounds
1
Assay Types
Binding — 138 assays, 12 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 113 12 6.2
assay format 16 0
cell-based format 9 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine